TNON Stock Analysis: Buy, Sell, or Hold?
TNON - Tenon Medical, Inc. Common Stock
$3.72
-0.05 (-1.33%)
▼
5d:
-25.6%
30d:
+2114.29%
90d:
+515.89%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When TNON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TNON is down 25.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TNON is down 25.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TNON is currently trading at $3.72, which is considered fair relative to its 30-day fair value range of $0.94 to $6.70.
Technical Outlook: Technically, TNON is in a uptrend. The price is currently testing key support at $3.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TNON scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.38 (+1092.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TNON is in a uptrend. The price is currently testing key support at $3.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TNON scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.38 (+1092.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.94 -
$6.70
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1092.9% below Wall St target ($44.38)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.94 -
$6.70
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.62
Resistance Level
$6.75
Current Trend
Uptrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.31
Wall Street Target
$44.38
(+1092.9%)
Revenue Growth (YoY)
126.8%
Profit Margin
-257.9%
Share & Embed Analysis
Last updated: September 04, 2026 6:43 PM ET
Data refreshes hourly during market hours. Next update: 7:43 PM
Data refreshes hourly during market hours. Next update: 7:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 43 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 46 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 49 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 43 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
